КАРТИРОВАНИЕ ПРОТЕОМА ПЛАЗМЫ КРОВИ ЧЕЛОВЕКА В НОРМЕ И ПРИ СВЕТЛОКЛЕТОЧНОМ РАКЕ ПОЧКИ
https://doi.org/10.17650/1726-9776-2011-7-3-65-69
Аннотация
Проведено масс-спектрометрическое картирование протеома плазмы крови больных почечно-клеточным раком (ПКР) и конт-рольной группы. Идентифицировано 247 белков, из них экспрессия 12 белков увеличивалась при переходе от данных контрольной группы к анализам больным с I−II и III−IV стадиями заболевания. Снижение экспрессии в этом ряду показывали 14 белков. Из 26 протеинов, показавших изменение экспрессии, 7 относятся к белкам острой фазы, 3 белка связаны с межклеточным матриксом. Данные белки могут быть потенциальными маркерами ПКР.
Об авторах
В. Е. Шевченко
РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия
Россия
С. В. Ковалев
РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия
Россия
В. А. Юрченко
РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия
Россия
В. Б. Матвеев
РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия
Россия
Д. Г. Заридзе
РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия
Россия
Список литературы
1. Ljungberg B., Cowan N.C., Hanbury D.C. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398–406.
2. Chow W.H., Dong L.M., Devesa S.S. Epidemiology and risk factors for kidney cancer. Nature Reviews Urology 2010;7:245−57.
3. Nickerson M.L., Jaeger E., Shi Y. et al. Improved identification of von Hippel-Lindau gene alternations in clear cell renal tumors. Clin Cancer Res 2008;14:4726–34.
4. Заридзе Д.Г. Профилактика рака. М.: ИМА-ПРЕСС, 2009.
5. Perroud B., Lee J., Valkova N. et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64−81.
6. Craven R.A., Stanley A.J., Hanrahan S. et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006;6:2853–64.
7. Banks R.E., Craven R.A., Harnden P. et al. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007;25:537–56.
8. Opatrná S., Chiangjong W., Korabecná M. et al. Plasma proteome profiling of von Hippel-Lindau disease after total and subtotal nephrectomy: a preliminary study. Clin Biochem 2010;43:142−9.
9. Eichelberg C., Junker K., Ljungberg B. et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009;55:851–63.
10. Janech M.G., Raymond J.R., Arthur J.M. Proteomics in renal research. Am J Physiol Renal Physiol 2007;292:F501–F512.
11. http://www.chem.agilent.com/Library/usermanuals/Public/5969-1597.pdf
12. http://www.chem.agilent.com/Library/usermanuals/Public/G2458-90003_SamplePrepGuide_online.pdf P. 67 77.
13. Martosella J., Zolotarjova N., Liu H. et al. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 2005;4:1522−37.
14. www.hppp.org
15. Saito K., Tatokoro M., Fujii Y. et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145–54.
16. Markiewski M.M., Lambris J.D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009;30:286−92.
17. Sadrzadeh S.M., Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004;121(Suppl):97−104.
18. Karpova M.A., Moshkovskii S.A., Toropygin I.Y. et al. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives. J Proteomics 2010;73:537−51.
19. Tolson J., Bogumil R., Brunst E. et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84:1220–1.
20. Ramankulov A., Lein M., Johannsen M. et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 2008;269:85−92.
21. Meyer H.A., Tulle A., Jung M. et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 2009;55:669–78.
22. Reichle A., Grassinger J., Bross K. et al. C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomark Insights 2007;1:87–98.
23. Zeng Z., Hincapie M., Haab B.B. et al. The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A 2010;1217:3307−15.
24. Kreunin P., Zhao J., Rosser C. et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007;6:2631−9.
25. Alvarez-Chaver P., Rodriguez-Piсeiro A.M., Rodriguez-Berrocal F.J. et al. Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int J Biochem Cell Biol 2007;39:529−40.
26. Cervi D., Pak B., Venier Н.L. et al. Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4. BMC Cancer 2010;10:258-258.
27. Fiedler G.M., Leichtle A.B., Kase J. et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 2009;15:3812−9.
28. Cervi D., Yip T.-T., Bhattacharya N. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008;111:1201−7.
29. Feldmann G., Mishra A., Hong S.M. et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010;70:4460−9.
30. Upadhyay A.K., Ajay A.K., Singh S. et al. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets 2008;8:741−52.
31. Haiman M., Salvenmoser W., Scheiber K. et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 2005;68:1130–6.
32. Hall A.K. Amplification-independent overexpression of thymosin beta-10 mRNA in human renal cell carcinoma. Ren Fail 1994;16:243−54.
33. Sparvero L.J., Asafu-Adjei D., Kang R. et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:7−17.
34. Liang X., Huuskonen J., Hajivandi M. et al. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics 2009;9:182−93.
35. Forstenberger G., Senn E., Morant R. et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 2006;15:64−8.
Рецензия
Для цитирования:
Шевченко В.Е., Ковалев С.В., Юрченко В.А., Матвеев В.Б., Заридзе Д.Г. КАРТИРОВАНИЕ ПРОТЕОМА ПЛАЗМЫ КРОВИ ЧЕЛОВЕКА В НОРМЕ И ПРИ СВЕТЛОКЛЕТОЧНОМ РАКЕ ПОЧКИ. Онкоурология. 2011;7(3):65-69. https://doi.org/10.17650/1726-9776-2011-7-3-65-69
For citation:
Shevchenko V.E., Kovalev S.V., Yurchenko V.A., Matveev V.B., Zaridze D.G. HUMAN PLASMA PROTEOME MAPPING IN HEALTH AND CLEAR CELL CARCINOMA OF THE KIDNEY. Cancer Urology. 2011;7(3):65-69. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-3-65-69
Просмотров:
739
Послать статью по эл. почте 
